Glax­o­SmithK­line moves malar­ia vac­cine pro­duc­tion to In­dia; Nevakar bags Eu­ro­pean part­ner and nine-fig­ure deal

GSK is shift­ing pro­duc­tion of its malar­ia vac­cine to a Covid-19 vac­cine de­vel­op­er in In­dia.

Wednes­day’s move to Bharat Biotech was made as part of ef­forts to bat­tle the dead­ly fever, as GSK’s vac­cine is the first to prove ef­fec­tive in com­bat­ing the dis­ease. Bharat will take over man­u­fac­tur­ing of the pro­tein part of the vac­cine while GSK con­tin­ues de­vel­op­ing the ad­ju­vant por­tion of the shot.

The vac­cine is cur­rent­ly be­ing pi­lot­ed in re­gions of Ghana, Kenya and Malawi un­der the Malar­ia Vac­cine Im­ple­men­ta­tion Pro­gram. More than 500,000 chil­dren have re­ceived the first dose since the pi­lots were ini­ti­at­ed by the three coun­tries in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER